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Abstract
Background: This retrospective study evaluated, according to hormone receptor status, the
antitumor effects of bisphosphonate especially on survival and disease progression in breast cancer
patients with metastatic bone disease.
Methods: Of 317 patients with initial bone metastasis and known breast cancer subtypes, 230
patients (72.6%) had hormone receptor (HR) positive tumors, and 87 patients (27.4%) had HR
negative tumors. We assessed the primary outcome of overall survival (OS), after adjusting for
other factors, comparing a group that received bisphosphonates (BPs) with a group that did not
receive it.
Results: 87.8% of HR positive and 69.0% of HR negative patients received BPs with a median
number of 17.7 cycles. Although BPs treatment made no survival benefit in HR positive group, HR
negative patients showed a significant prolonged survival when they received BPs treatment (hazard
ratio = 0.56 [95% CI 0.34 to 0.91], P = 0.019). In multivariate analysis, disease free interval > 2 years
(P = 0.036), a sum of metastatic sites < 3 (P = 0.034), and BP treatments (P = 0.007) were significant
factors for survival in HR negative patients.
Conclusion: Bisphosphonate treatment can result in a survival benefit in metastatic breast cancer
patients with HR negative tumors.
Background
Bone metastases are common in patients with advanced
breast cancer. The median survival time after the diagnosis
of bone metastases is approximately two years, although
it may increase with new treatment regimens [1]. As
patients survive longer, the incidence of associated prob-
lems with metastatic bone disease (MBD), such as patho-
logic fracture or spinal cord compression, increases, and
these complications may substantially reduce a patient's
quality of life [1,2]. Over the past decade, bisphospho-
nates (BPs) have become the standard therapy for breast
cancer patients with bone metastasis. It is now clear that
the bisphosphonates reduce both the symptoms and com-
plications of bone involvement [3]. In addition, the anti-
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tumor activities of BPs have been explored, particularly
with zoledronate and pamidronate, through in-vitro  as
well as in-vivo animal studies [4-6]. These preclinical stud-
ies showed that BPs could reduce visceral metastasis as
well as bone metastasis. However, the clinical relevance of
the antitumor effects of BPs has not been firmly estab-
lished. A few small pilot studies investigating the potential
roles of BPs in the adjuvant setting were conducted, and
their results regarding the antitumor effects of BPs were
controversial, due to the non-randomized nature of these
studies [7-9].
Recently, Gnant et al. reported that zoledronate, in an
adjuvant setting, significantly prolonged disease-free sur-
vival beyond the time achieved with endocrine therapy
alone (hazard ratio = 0.64, P = 0.01) [10]. Now, several
large randomized controlled trials, such as the B-34 trial,
the Adjuvant Zoledronic Acid to Reduce Recurrence
(AZURE) trial, and the SWOG 0307 trial, are being con-
ducted to clarify the roles of BPs in the adjuvant setting.
These studies will assess the direct or indirect antitumor
effects of BPs, according to the rate of bone metastasis,
other visceral metastasis, and overall survival.
The antitumor effects of BPs have not been investigated in
the metastatic setting, although BPs are now widely used
in metastatic breast cancer. Most studies focused on the
development of skeletal related events (SREs) and the
quality of life of patients with metastatic bone disease
[11]. In this retrospective study, we address the antitumor
effect of BPs in breast cancer patients with metastatic bone
disease. Our primary objective is to assess the association
between BP treatment and overall survival (OS), while
adjusting for other factors. The secondary objective is to
evaluate the effects of BPs in preventing SREs and the pro-
gression of metastatic bone disease.
Methods
Study population and study assessments
This retrospective study included a total of 317 breast can-
cer patients with initial bone metastases, whose hormone
receptor (HR) status and HER2 status were known, and
who were treated between June 2001 and July 2007 at the
National Cancer Center Hospital, Korea. Of these, 87
patients (27.4%) had HR negative tumors. A tumor was
considered to be HER2 positive if the primary or meta-
static tumor was scored 3+ by HER2 immunohistochem-
istry (IHC) or by amplification of the HER2 gene by the
method of fluorescent in situ hybridization (FISH). If a
tumor's score was 2+ by IHC, the tumor was reanalyzed
using FISH. Metastatic bone disease (MBD) was diag-
nosed mostly by means of radionuclide bone scans per-
formed for follow-up. Magnetic resonance imaging was
done when patients showed skeletal related symptoms
such as pain, fractures, or neurologic signs with equivocal
bone scan results.
Patients with bone metastases were followed up until
August 2008, and their medical records were reviewed for
clinical data, including age at the initial diagnosis, age at
diagnosis of disease recurrence, initial stage of the disease,
pathological type, disease-free interval, number and site
of metastases, treatment after diagnosis, especially
bisphosphonate treatment, and survival interval from the
diagnosis of disease recurrence or initial stage IV presenta-
tion.
The administered bisphosphonates (BPs) differed accord-
ing to the periods of treatment, compliance, tolerability,
and insurance strategy. The types of bisphosphonate used
were zoledronate or pamidronate. These drugs were given
at three or four week intervals. Patients who received more
than three consecutive months of bisphosphonate treat-
ment were designated as members of the bisphosphonate
group (BP group), and other patients were designated as
members of the non-bisphosphonate group (non-BP
group).
For the evaluation of the bisphosphonate effect on bone
metastasis, we assessed the progression of bone metasta-
sis, time to progression of bone disease (TTP_BD), and
development of skeletal related events (SREs). SREs were
defined as pathological fractures, or surgery or palliative
radiation to bone in order to treat or prevent impending
fractures or cord compressions. Disease progression in
bone was defined as the appearance of any new bone
lesions, or the progression of existing bone metastases,
including the development of SREs. To monitor the side
effects of bisphosphonate, the serum levels of creatinine
and total calcium were regularly checked. Bisphosphonate
treatment was temporarily stopped before and after dental
procedures. Patients undergoing bisphosphonate treat-
ment were instructed to take an oral calcium supplement
containing vitamin D.
This study protocol was approved by the Institutional
Review Board for the National Cancer Center (IRB proto-
col number NCCNCS 08-195). Because this was a retro-
spective analysis that involved no additional risk to
patients, the Institutional Review Board approved a
waiver of informed consent.
Statistical methods
Descriptive statistics, including sample size, median, and
range, were reported for continuous variables. Discrete
variables were summarized using frequencies and per-
centages. Clinical parameters and treatment response
were compared using 2-way tables, chi-square, and Mann-
Whitney U test. Time to progression of bone diseaseBMC Cancer 2009, 9:154 http://www.biomedcentral.com/1471-2407/9/154
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(TTP_BD) and overall survival (OS) were estimated by
Kaplan-Meier analysis and compared using the log-rank
test. Cox proportional hazard model was used to identify
the independent predictive factors that significantly influ-
enced the overall survival of patients with metastatic bone
disease. The proportionality assumption for the Cox
regression and the log rank test was checked and verified
by using the log-log plot. All P values were 2-tailed, with
5% significance levels. All statistics were calculated using
SPSS® 13.0 software (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
Among 317 patients with bone metastases at diagnosis,
262 (82.6%) patients were treated with BPs during follow-
up. The median number of cycles of BP treatment was
17.7 (range, 3 to 57 cycles), and the median interval
between cycles was 31 days. Patients' characteristics are
shown in Table 1. Types of BP were zoledronate (27.5%),
pamidronate (40.1%), and ibandronate (0.8%). Eighty-
three (31.6%) patients received more than one type of BP,
sequentially. Aside from more weight bearing bone
involvement (P < 0.001), the BP group had better prog-
nostic factors, such as HR positivity (P < 0.001), negative
HER2 receptors (P = 0.035), fewer visceral metastases (P =
0.002), bone only metastases (P = 0.014), and fewer met-
astatic sites (P = 0.006), compared to the non-BP group.
There was no significant difference in use of anti-HER2
therapy between BP and non-BP groups.
The log-log plot showed that the proportionality assump-
tion was satisfied (data not shown). Although the rate of
progression of bone disease and the incidence of SREs
(except for the first event) were higher in the BP group,
there was no statistical difference in the time to progres-
sion of the bone disease (TTP_BD) according to BP treat-
ment (P = 0.059). The overall survival (OS) was
significantly longer in the BP group (Fig. 1).
In the univariate analysis, the following factors, in addi-
tion to BP treatment, showed positive association with
longer survival: HR positivity, HER2 negativity, disease
free interval (DFI) > 2 years, sum of metastatic sites < 3,
and no visceral involvement (Table 2). Among these fac-
tors, HR positivity, DFI > 2 years, and no visceral metasta-
sis were significant in multivariate Cox analysis.
Table 1: Characteristics of total patients with metastatic bone disease
Factors BP group
N = 262
Non-BP group
N = 55
P-value||
Age, median years (range) 45.5 (25–77) 50 (30–68) NS*
PS** (ECOG ≥ 2) 10/166 (6.0%) 2/27 (7.4%) NS
Pre-menopausal 79/176 (44.9%) 7/30 (23.3%) 0.027
Post-menopausal 97/176 (55.1%) 23/30 (76.7%)
ER***/PR† positive 202 (77.1%) 28 (50.9%) < 0.001
HER2 positive 72 (27.5%) 23 (41.8%) 0.035
DFI‡ (month, median, range) 25 (0–230) 21 (0–174) NS
Initial stage IV 61 (23.4%) 11 (20%) NS
Adjuvant treatment
Radiotherapy 111 (42.4%) 27 (49.1%) NS
Chemotherapy 176 (67.2%) 38 (69.1%) NS
Hormonal therapy 127 (48.5%) 21 (38.2%) NS
Metastatic sites
Visceral (liver, lung) 116 (44.3%) 37 (67.3%) 0.002
LNs§ 119 (45.4%) 30 (54.5%) NS
Soft tissue 78 (29.8%) 20 36.4%) NS
Bone only 81 (30.9%) 8 (14.5%) 0.014
Weight bearing bone involvement 225 (86.2%) 25 (45.5%) < 0.001
Sum of metastatic sites (range) 2 (1–6) 3 (1–6) 0.006
Cycles of palliative chemotherapy NS
1 36 (13.7%) 8 (14.5%)
2 53 (20.2%) 13 (23.6%)
≥ 3 157 (59.9%) 29 (52.7%)
Palliative AI¶ use 168 (64.1%) 23 (41.8%) 0.002
Palliative anti-HER2 therapy 58/72 (80.6%) 20/23 (86.9%) NS
Disease progression in bone (n) 97 (47.8%) 21 (38.2%) NS
SREs (except the first event) 63 (27.2%) 21 (24.7%) NS
Abbreviations:*, not significant; **, performance status; ***, estrogen receptor; †, progesteron receptor;
‡, disease free interval; § lymph nodes; ¶ aromatase inhibitor; ||, P-value was obtained by chi-square test except variables of age and DFI which were 
obtained through Mann-Whitney U testBMC Cancer 2009, 9:154 http://www.biomedcentral.com/1471-2407/9/154
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It has been known that patients with hormone receptor
(HR) positive tumors tend to develop more bone metas-
tasis than those with HR negative tumors. As shown in
Table 1, our study population reflected this trend. When
we conducted the survival analysis of all patients, longer
survival was associated with BP treatment as well as with
HR positivity (Table 2). We therefore analyzed the effect
of BP treatment on survival after stratifying HR status into
HR positive and HR negative groups because we wanted to
exclude the possible role of HR positivity as a confound-
ing factor.
The effect of BP treatment in the HR positive group
Of the 230 patients whose tumors were HR positive, 202
patients (87.8%) received BP treatments. Although more
patients in the BP group developed disease progression in
bone and of SREs (except for the first event), these associ-
ations were not statistically significant (Table 3). There
was no significant difference in TTP_BD or OS associated
with BP treatment (P = 0.117, P = 0.104 respectively) (Fig.
2).
HER2 receptor positivity and visceral organ involvement
were important factors in OS. These results were con-
firmed through multivariate analysis. However, BP treat-
ment was not a significant component for OS in HR
positive patients (Table 4).
The effect of BP treatment in the HR negative group
Of the remaining 87 patients with bone metastasis whose
tumors were HR negative, 60 (69%) patients were treated
with BP for metastatic bone disease. There was no signifi-
Total patients with metastatic bone disease Figure 1
Total patients with metastatic bone disease. (A) TTP_BD (P = 0.059), (B) OS (P < 0.001).
Table 2: Analysis for OS of total patients
Univariate Multivariate
Variables Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age <40 0.86 (0.66–1.13) 0.29 - -
Post-menopausal state 1.11 (0.77–1.59) 0.59 - -
DFI* >2 yr 0.63 (0.48–0.83) 0.001 0.65 (0.48–0.86) 0.003
Initial stage IV 0.93 (0.67–1.29) 0.66 - -
ER**/PR*** positive 0.36 (0.27–0.48) < 0.001 0.41 (0.31–0.56) < 0.001
HER2 positive 1.50 (1.13–1.98) 0.005 0.94 (0.69–1.28) 0.69
Visceral metastasis 2.02 (1.55–2.65) < 0.001 1.93 (1.39–2.68) < 0.001
Sum of metastasis sites ≥ 3 1.53 (1.17–2.00) 0.002 0.99 (0.73–1.37) 0.96
BP† use 0.52 (0.37–0.73) < 0.001 0.70 (0.50–0.98) 0.96
Abbreviations: *, disease free interval; **, estrogen receptor; ***, progesteron receptor; †, bisphosphonate;.BMC Cancer 2009, 9:154 http://www.biomedcentral.com/1471-2407/9/154
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Patients with HR positive metastatic bone disease Figure 2
Patients with HR positive metastatic bone disease. (A) TTP_BD (P = 0.117), (B) OS (P = 0.104).
Table 3: Characteristics of patients with HR positive and HR negative tumor
HR* positive tumor HR negative tumor
Factors BP group
N = 202
Non-BP group
N = 28
P-value|| BP group
N = 60
Non-BP group
N = 27
P-value||
Age (yr, median, range) 46 (28–77) 50.5 (33–68) NS** 43.5 (25–69) 50 (30–67) NS
PS*** (ECOG ≥ 2) 9/138 (6.5%) 0/16 (0%) NS 1/28 (3.6%) 2/11 (18.2%) NS
Pre-menopausal 66/144(45.8%) 4/18 (22.2%) 0.057 13/32 (40.6%) 3/12 (25%) NS
Post-menopausal 78/144(54.2%) 14/18 (77.8%) 19/32 (59.4%) 9/12 (75%)
HER2 positive 44 (21.8%) 12 (42.9%) 0.015 28 (46.7%) 11 (40.7%) NS
DFI† (months, median, range) 27.5 (0–230) 26 (82.1%) NS 18.5 (0–86) 18 (0–174) NS
Initial stage IV 44 (21.8%) 4 (14.3%) NS 17 (28.8%) 7 (25.9%) NS
Adjuvant treatment
Radiotherapy 82 (40.6%) 15 (53.6%) NS 29 (48.3%) 12 (44.4%) NS
Chemotherapy 139 (68.8%) 21 (75%) NS 37 (61.7%) 17 (63%) NS
Hormonal therapy 114 (56.4%) 17 (60.7%) NS 13 (21.7%) 4 (14.8%) NS
Metastatic sites
Visceral (liver, lung) 80 (39.6%) 18 (64.3%) 0.013 36 (60%) 19 (70.4%) NS
LNs‡ 87 (43.1%) 12 (42.9%) NS 32 (53.3%) 18 (66.7%) NS
Soft tissue 57 (28.2%) 8 (28.6%) NS 21 (35%) 12 (44.4%) NS
Bone only 73 (36.1%) 6 (21.4%) NS 8 (13.3%) 2 (7.4%) NS
Weight bearing bone involvement 174 (86.6%) 13 (46.4%) < 0.001 51 (85%) 12 (44.4%) < 0.001
Sum of metastatic sites (range) 2 (1–6) 3 (1–5) NS 3 (1–5) 3 (1–6) NS
Cycles of palliative chemotherapy NS NS
1 27 (13.4%) 4 (14.3%) 9 (15%) 4 (14.8%)
2 43 (21.3%) 3 (10.7%) 10 (16.7%) 10 (37%)
≥ 3 116 (57.4%) 17 (60.7%) 41 (68.3%) 12 (44.4%)
Palliative AI§ use 159 (78.7%) 21 (75%) NS 9 (15%) 2 (7.4%) NS
Palliative anti-HER2 therapy 35/44 (79.5%) 10/12 (83.3%) NS 23/28 (82.1%) 10/11 (90.9%) NS
Disease progression in bone 96 (47.5%) 10 (35.7%) NS 23 (38.3%) 6 (22.2%) NS
SREs (except the first event) 59 (29.2%) 4 (14.3%) NS 15 (25%) 4 (14.8%) NS
Abbreviations: *, hormone receptor; **, not significant; ***, performance status; †, disease free interval; ‡, lymph nodes;
§ aromatase inhibitor; ||, P-value was obtained via chi-square test except variables of age and DFI which were obtained through Mann-Whitney U 
test.BMC Cancer 2009, 9:154 http://www.biomedcentral.com/1471-2407/9/154
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cant difference in the baseline characteristics between the
BP and the non-BP groups, except that more patients had
weight bearing bone metastases in the BP group com-
pared to the non-BP group (P < 0.001) (Table 3). The rate
of disease progression in bone metastases and SREs
(except for the first event) was greater in the BP group.
However, the difference was not significant (P = 0.14, P =
0.29, respectively). TTP_BD was not significantly different
between the two groups (Fig. 3).
Unlike the OS observed in the HR positive patients, OS
was significantly prolonged in the BP group (median, 1.7
yr vs. 1.3 yr, P = 0.040, Fig. 3). In univariate analysis for
OS, disease free interval > 2 years (hazard ratio = 0.61
[95% CI 0.38 to 0.98], P = 0.040), a sum of metastatic
sites ≥ 3 (hazard ratio = 1.83 [95% CI 1.13 to 2.97], P =
0.014), and BP treatments (hazard ratio = 0.56 [95% CI
0.34 to 0.91], P = 0.019) were significant factors for sur-
vival in HR negative patients. These results were verified
through multivariate analysis (Table 4).
Table 4: Analysis for OS of patients according to hormone receptor status
HR positive patients HR negative patients
Univariate Multivariate Univariate Multivariate
Variables Hazard ratio 
(95% CI)
P-value Hazard ratio 
(95% CI)
P-value Hazard ratio 
(95% CI)
P-value Hazard ratio 
(95% CI)
P-value
Age < 40 yr 0.85
(0.60–1.19)
0.344 - - 0.75
(0.47–1.21)
0.237 - -
Postmenopausal 
state
1.26
0.81–1.94)
0 . 3 0 2 ------
HER2 positive 1.66
(1.15–2.40)
0.007 1.54
(1.06–2.23)
0.022 0.67
(0.43–1.06)
0.088 - -
DFI* > 2 yr 0.76
(0.54–1.07)
0.12 - - 0.61
(0.38–0.98)
0.040 0.59
(0.36–0.97)
0.036
Initial stage IV 0.76
(0.49–1.19)
0.232 - - 0.96
(0.58–1.59)
0.882 - -
Sum of metastasis 
sites ≥ 3
1.32
(0.94–1.83)
0.105 - - 1.83
(1.13–2.97)
0.014 1.70
(1.04–2.78)
0.034
Visceral metastasis 1.78
(1.28–2.48)
0.001 1.7
(1.22–2.38)
0.002 - - - -
BP** use 0.67
(0.42–1.19)
0.111 - - 0.56
(0.34–0.91)
0.019 0.50
(0.30–0.83)
0.007
Abbreviations: *, disease free interval; **, bisphosphonate.
Patients with HR negative metastatic bone disease Figure 3
Patients with HR negative metastatic bone disease. (A) TTP_BD (P = 0.163), (B) OS (P = 0.040).BMC Cancer 2009, 9:154 http://www.biomedcentral.com/1471-2407/9/154
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Discussion
BPs have been used for more than 15 years to improve the
outcomes of patients with bone metastases from solid
tumors, as well as hematologic malignancies. In bone
metastases, the cancer cells invade the bone marrow cavity
and produce parathyroid hormone-related protein (PTH-
rP), which stimulates osteoclastic resorption by increasing
the production of the receptor activator of the nuclear fac-
tor-κB ligand (RANKL) by osteoblast and stromal cells.
The RANKL binds to its receptor, RANK, on osteoclast lin-
eage cells, induces differentiation into mature osteoclasts,
and stimulates osteoclast activity [12,13]. Nitrogen-con-
taining BPs (N-BPs) such as zoledronate, pamidronate,
and ibandronate affect osteoclast activity and survival
through inhibiting farnesyl diphosphonate synthase in
the mevalonate pathway [13]. This inhibition also seems
to account for the antitumor effects of N-BPs in vitro [14].
N-BPs also have anti-angiogenic effects, decreasing the
serum VEGF of patients with a variety of solid tumors
[15]. Inhibition by N-BPs enhanced the antitumor activity
of known cytotoxic agents that were commonly used in
clinical settings [16]. Among various BPs, N-BPs, espe-
cially zoledronate, have the strongest antitumor effect in
vitro [17].
In contrast to the consistent preclinical antitumor effects
of BPs, the results of clinical studies in breast cancer have
shown conflicting findings. Diel and Powles indicated
that clodronate treatment prevented skeletal metastases
with no effect on visceral metastases, and improved over-
all survival [7,18-20]. However, Saarto reported that
clodronate treatment worsened survival, especially in hor-
mone negative patients, among whom significantly more
patients on clodronate experienced non-skeletal metas-
tases than among the control group [8].
In this study, we investigated the effect of BP in a meta-
static setting, specifically in patients with metastatic bone
disease from breast cancer. The most important limitation
of this retrospective study is that the use of BPs was based
on the clinical decision to prevent complications such as
pathological fracture, bone pain, and hypercalcemia.
Patients who had experienced SREs secondary to bone
metastasis tended to be put on bisphosphonate more
often. Consequently, patients with BP group in this study
developed more often progression of bone disease and
SREs, because BP treated group had more advanced and
complicated bone disease at the outset of BP use. Con-
versely, patients with bone metastasis who did not have
symptoms or had only minimal tumor burden tended not
to receive BP treatment. Therefore, patients with more
indolent bone disease had greater propensity to be
included in the non-BP group. With these inherent unbal-
ances, TTP_BD was not significantly different according to
BP treatment in both HR positive and HR negative groups.
In the first analysis, including all patients with metastatic
bone disease, favorable OS was expected in the BP group,
as a result of an imbalance in hormone receptor status, the
presence of visceral organs involvement, and other impor-
tant prognostic factors. It was still possible that BP treat-
ment was an important factor for survival because far
more patients with HR positive tumors received BP treat-
ment. In the next analysis, we corrected for this confound-
ing factor by looking separately at patients with HR
positive tumors within the BP-treated vs. untreated
groups. In these patients, HER2 positivity and visceral
organ involvement were important factors for OS, but
there was no significant difference in OS with or without
BP treatment. In HR negative patients, on the contrary, an
OS difference was significant in favor of the BP treatment.
HR negative patients' characteristics were well balanced
between the BP treated and untreated groups. There was
no concern for a possible interaction between hormonal
therapy and BPs in HR negative patients.
These results are contrary to those of Saarto's clodronate
study. In that study, 10-year disease free survival was
much worse in the clodronate treatment group, especially
in estrogen receptor (ER) negative patients [8]. It was
assumed that antiestrogen might have opposed the detri-
mental effect of BPs. However, this proposition lacks a
biological rationale. To the best of our knowledge, no
published studies explored the relationship between hor-
mone receptor status and the effect of BP treatment in
patients with bone metastasis. Cross et al. observed a
more frequent expression of RANKL in estrogen negative
patients with a high histologic grade breast cancer. They
observed a significant negative relation between the
expression of RANKL and tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) [21]. In other words,
estrogen negative tumors showed higher RANKL expres-
sion and lower TRAIL expression. Therefore, BP treatment
could be more beneficial to ER negative tumors through
suppressing RANKL production by osteoblast and other
stromal cells.
In this study, it may appear that there were unexpected
interactions of anti-hormonal treatment with BPs in HR
positive patients. Recently, studies of the role of zoledro-
nate in preventing treatment-induced bone loss in pre-
and post-menopausal breast cancer patients were per-
formed. They showed that hormonal treatment combined
with zoledronate did not influence the survival or disease
progression in hormone responsive breast cancer [22,23].
Further studies are needed to fully elucidate the effects of
BPs in HR positive tumors.
Another limitation of this study was that patients receiv-
ing different N-BPs were included. Variation in the N-BPs
made it difficult to compare the efficiency among the N-BMC Cancer 2009, 9:154 http://www.biomedcentral.com/1471-2407/9/154
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BPs zoledronate and pamidronate. There is preclinical
data showing that zoledronate is much more potent than
other BPs. However, this has not been confirmed in clini-
cal settings. Clinically, the choice among the various N-
BPs is dependent on the adherence of patients and prefer-
ence of clinicians [11].
Conclusion
We conclude that BP treatment may give a survival benefit
in metastatic breast cancer patients, particularly in
patients with HR negative tumors, which are known to
have a poorer prognosis. We believe that this analysis
adds insight into the roles of BPs in metastatic breast can-
cer, in addition to their ancillary role in supportive care.
Based on these results, new strategies could be investi-
gated for the possible benefits of BP treatment in meta-
static breast cancer patients without bone involvement.
Abbreviations
HR: hormone receptor; BPs: bisphosphonates; N-BPs:
nitrogen containing bisphosphonates; OS: overall sur-
vival; DFI: disease free interval; MBD: metastatic bone dis-
ease; SREs: skeletal related events; TTP_BD: time to
progression of bone disease; IHC: immunohistochemis-
try; FISH: fluorescent in situ hybridization; RANKL: recep-
tor activator of the nuclear factor-κB ligand; TRAIL: tumor
necrosis factor-related apoptosis-inducing ligand.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
IHP and JR designed the study and conducted the data
acquisition. IHP and BHN performed the statistical analy-
sis. IHP, JR and BHN participated in the interpretation of
the data. IHP and JR drafted and revised the manuscript.
IHP, JR, BHN, YK and KSL participated in critical review of
the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This study was supported by NCC Grant No-0610240.
References
1. Coleman RE: Metastatic bone disease: clinical features, patho-
physiology and treatment strategies.  Cancer Treat Rev 2001,
27(3):165-176.
2. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman
KA: Health-related quality of life among patients with breast
cancer receiving zoledronic acid or pamidronate disodium
for metastatic bone lesions.  Med Care 2004, 42(2):164-175.
3. Coleman RE: Bisphosphonates in breast cancer.  Ann Oncol 2005,
16(5):687-695.
4. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T: Zoledronic
acid inhibits visceral metastases in the 4T1/luc mouse breast
cancer model.  Clin Cancer Res 2004, 10(13):4559-4567.
5. Winter MC, Holen I, Coleman RE: Exploring the anti-tumour
activity of bisphosphonates in early breast cancer.  Cancer
Treat Rev 2008, 34(5):453-475.
6. Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T: Zoledronic
acid – a multiplicity of anti-cancer action.  Curr Med Chem 2007,
14(20):2126-2135.
7. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, Schuetz
F: Adjuvant oral clodronate improves the overall survival of
primary breast cancer patients with micrometastases to the
bone marrow – a long-term follow-up.  Ann Oncol 2008,
19(12):2007-2011.
8. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C: Ten-year follow-
up of a randomized controlled trial of adjuvant clodronate
treatment in node-positive breast cancer patients.  Acta Oncol
2004, 43(7):650-656.
9. Kohno N, Kokufu I: Prevention of bone metastases from breast
cancer by adjuvant bisphosphonate therapy.  Breast Cancer
2003, 10(1):33-37.
10. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G,
Poestlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radi-
sic V, et al.: Endocrine therapy plus zoledronic acid in premen-
opausal breast cancer.  N Engl J Med 2009, 360(7):679-691.
11. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa
L, Crino L, Dirix L, Gnant M, Gralow J, et al.: Guidance on the use
of bisphosphonates in solid tumours: recommendations of
an international expert panel.  Ann Oncol 2008, 19(3):420-432.
12. Coleman R: Potential use of bisphosphonates in the preven-
tion of metastases in early-stage breast cancer.  Clin Breast Can-
cer 2007, 7(Suppl 1):S29-35.
13. Mundy GR: Metastasis to bone: causes, consequences and
therapeutic opportunities.  Nat Rev Cancer 2002, 2(8):584-593.
14. Roelofs AJ, Thompson K, Gordon S, Rogers MJ: Molecular mecha-
nisms of action of bisphosphonates: current status.  Clin Cancer
Res 2006, 12(20 Pt 2):6222s-6230s.
15. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M,
Salerno A, Denaro V, Tonini G: Pamidronate induces modifica-
tions of circulating angiogenetic factors in cancer patients.
Clin Cancer Res 2002, 8(5):1080-1084.
16. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI: The
bisphosphonate, zoledronic acid, induces apoptosis of breast
cancer cells: evidence for synergy with paclitaxel.  Br J Cancer
2001, 84(8):1126-1134.
17. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter
CD, Ebetino FH, Rogers MJ: Structure-activity relationships for
inhibition of farnesyl diphosphate synthase in vitro and inhi-
bition of bone resorption in vivo by nitrogen-containing
bisphosphonates.  J Pharmacol Exp Ther 2001, 296(2):235-242.
18. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D,
Kaufmann M, Bastert G: Reduction in new metastases in breast
cancer with adjuvant clodronate treatment.  N Engl J Med 1998,
339(6):357-363.
19. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosen-
qvist K, Smith I, Ottestad L, Legault S, et al.: Randomized, placebo-
controlled trial of clodronate in patients with primary oper-
able breast cancer.  J Clin Oncol 2002, 20(15):3219-3224.
20. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A,
Ashley S, Smith I, Ottestad L, Kanis J: Reduction in bone relapse
and improved survival with oral clodronate for adjuvant
treatment of operable breast cancer [ISRCTN83688026].
Breast Cancer Res 2006, 8(2):R13.
21. Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA,
Reed MW, Holen I: Expression of receptor activator of nuclear
factor kappabeta ligand (RANKL) and tumour necrosis fac-
tor related, apoptosis inducing ligand (TRAIL) in breast can-
cer, and their relations with osteoprotegerin, oestrogen
receptor, and clinicopathological variables.  J Clin Pathol 2006,
59(7):716-720.
22. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaess-
mann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittl-
boeck M, et al.: Zoledronic acid prevents cancer treatment-
induced bone loss in premenopausal women receiving adju-
vant endocrine therapy for hormone-responsive breast can-
cer: a report from the Austrian Breast and Colorectal
Cancer Study Group.  J Clin Oncol 2007, 25(7):820-828.
23. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C,
Hohneker J, Lacerna L, Petrone S, Perez EA: Zoledronic acid inhib-
its adjuvant letrozole-induced bone loss in postmenopausal
women with early breast cancer.  J Clin Oncol 2007,
25(7):829-836.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2009, 9:154 http://www.biomedcentral.com/1471-2407/9/154
Page 9 of 9
(page number not for citation purposes)
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/154/pre
pub